(Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results